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ABSTRACT
Objectives To investigate how the COVID-19 pandemic 
affected the number of people aged 50+ years 
presenting to primary care with features that could 
potentially indicate cancer, and to explore how reporting 
differed by patient characteristics and in face- to- face vs 
remote consultations.
Design, setting and participants A retrospective cohort 
study of general practitioner (GP), nurse and paramedic 
primary care consultations in 21 practices in South- West 
England covering 123 947 patients. The models compared 
potential cancer indicators reported in April–July 2019 
with April–July 2020.
Main outcome measures Potential indicators of cancer 
were identified using code lists for symptoms, signs, test 
results and diagnoses listed in the National Institute for 
Health and Care Excellence suspected cancer referral 
guidance (NG12).
Results During April–July 2019, 17% of registered 
patients aged 50+ years reported a potential cancer 
indicator in a consultation with a GP or nurse. During 
April–July 2020, this reduced to 11% (incidence rate ratio 
(IRR) 0.64, 95% CI 0.62 to 0.67, p<0.001). Reductions in 
potential cancer indicators were stable across age group, 
sex, ethnicity, index of multiple deprivation quintile and 
shielding status, but less marked in patients with mental 
health conditions than without (IRR 0.75, 95% CI 0.72 to 
0.79, interaction p<0.001). Proportions of GP consultations 
with potential indicators of cancer reduced between 
2019 and 2020 for face- to- face consultations (IRR 0.84, 
95% CI 0.76 to 0.92, p<0.001) and increased for remote 
consultations (IRR 1.17, 95% CI 1.07 to 1.29, p=0.001), 
although it remained lower in remote consulting than face- 
to- face in April–July 2020. This difference was greater for 
nurse/paramedic consultations (face- to- face: IRR 0.61, 
95% CI 0.44 to 0.83, p=0.002; remote: IRR 1.60, 95% CI 
1.10 to 2.333, p=0.014).
Conclusion The number of patients consulting with 
presentations that could potentially indicate cancer 
reduced during the first wave of the COVID-19 pandemic. 
Patients should be encouraged to continue contacting 
primary care for persistent signs and symptoms, and 
GPs and nurses should be encouraged to probe patients 
for further information during remote consulting, in the 
absence of non- verbal cues.
INTRODUCTION
In March 2020, WHO declared COVID-19 
a pandemic,1 and the UK went into lock-
down; the public were instructed to ‘stay at 
home, protect the National Health Service 
and save lives’.2 Primary care providers were 
advised to provide all consultations remotely, 
unless a face- to- face consultation was urgently 
required,3 in order to reduce contact and the 
spread of the virus. Patients at particularly 
high risk of severe COVID-19 due to age or 
pre- existing health conditions were advised 
to ‘shield’ and avoid all but essential contact.
General practitioner (GP) and nurse 
consulting rates markedly dropped in April–
May 2020 during the period of UK lockdown, 
but had largely returned to normal by July 
2020,4 with the majority of consultations 
carried out remotely (mostly via telephone).
There are fears that reduced consulting 
during the lockdown period and changes in 
consultation provision may have adversely 
impacted on cancer detection.5 There was a 
Strengths and limitations of this study
 ► We were able to use a large number of patients 
(>126 000) aged 50+ years from a diverse range of 
backgrounds, and a comprehensive list of potential 
cancer indicators.
 ► We were able to identify the number of patients 
presenting to primary care with symptoms, signs, 
test results or diagnoses, which could potentially 
indicate cancer, and to explore how this reporting 
differed by patient characteristics and consultation 
provision.
 ► We were unable to take account of whether symp-
toms were persistent or unexplained, which may 
inflate our estimates of potential cancer indicators.
 ► Some symptoms and signs may have been reported 
in free text rather than using clinical codes or may 
have been recorded in administration notes not as-
sociated with consultations.
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63% reduction in skin cancer diagnosis in England in the 
first 3 months of the pandemic6 and 3500 fewer colorectal 
cancer diagnoses than expected in the first 6 months.7 
This pattern is not limited to the UK. An analysis on the 
Danish registry showed cancer diagnosis in Denmark 
dropped by 33% from March to May 20208 and similar 
reductions have been observed in the Netherlands.9
These concerning reductions in diagnoses are likely 
to result from a combination of factors, including 
temporary suspensions in cancer screening services,10 11 
reduced capacity in secondary care and less reporting 
of potential cancer symptoms in primary care. A Cancer 
Research UK survey suggested GPs perceived they 
received fewer reports of cancer symptoms, particularly 
from older people, after the pandemic than before.5 This 
could be related to changes in the willingness of patients 
to disclose symptoms, or changes in patient or doctor 
behaviour associated with the shift to remote consulta-
tions. Reduced symptom reporting could result in late 
diagnoses, increased workload for cancer services and 
poorer patient outcomes.12 A modelling study showed 
that delays in cancer diagnosis in this period could result 
in approximately 3330 deaths for breast, colorectal, lung 
and oesophageal cancer alone.13
The aim of this study was to investigate how the 
COVID-19 pandemic affected the number of people aged 
50 years and over presenting to primary care with symp-
toms, signs, test results or diagnoses, which could poten-
tially indicate cancer, and to explore how this reporting 
differed by patient characteristics and consultation provi-
sion (ie, face- to- face vs remote).
METHODS
Design and setting
This was a retrospective cohort study of primary care 
consultations in 21 practices in Bristol, North Somerset 
and South Gloucestershire, a region in the South West 
of England. Data were extracted for the RAPCI study 
(rapid COVID-19 intelligence to improve primary care 
response), a mixed- methods study on how general prac-
tices coped with rapid change to remote consulting in 
the initial months of the COVID-19 pandemic. The main 
results are reported elsewhere.4
Data
All 82 practices in Bristol, North Somerset and South 
Gloucestershire were approached by the Clinical 
Commissioning Group (CCG) with information about 
the study. Practices returned expressions of interest to the 
researchers who selected 21 practices, aiming for a varia-
tion of deprivation, ethnic mix, practice size and locality. 
All participating practices then agreed for anonymised 
data to be extracted directly from the patient record by 
One Care, the GP federation in Bristol, North Somerset 
and South Gloucestershire CCG. One Care provide tech-
nical support and management information services to 
GP practices in the CCG and have the ability to extract 
routine data from the patient record via the EMIS enter-
prise search and report module. All practices use the 
same EMIS electronic medical records system. Data on all 
patients registered on 1 July 2020 were included. Patient 
data included demographics (age, sex, ethnicity and 
deprivation) and clinical characteristics (such as mental 
health and shielding status). Data were obtained on all 
consultations added to the system by clinical staff, and all 
clinical codes added during those consultations between 
February 2019 and July 2020 inclusive. We extracted data 
from February 2019 so that we had a full 18 months to 
examine trends for the main study. For the analyses in 
this paper, the period April–July 2020 (ie, the period 
since the start of UK lockdown) was compared with the 
same period the previous year (April–July 2019). For this 
paper, we restricted the analysis to patients aged 50 years 
and over as cancer is relatively rare in younger age groups.
Consultations
A consultation was defined as an interaction between a 
patient and a GP, nurse or paramedic working in general 
practice. We focused on GP and nurse/paramedic consul-
tations because the number of cancer indicators reported 
in consultations with other health professionals was very 
small. We excluded consultations recorded by administra-
tors or other healthcare professionals, and administrative 
tasks recorded by clinicians. Remote consultations were 
defined as those carried out by telephone, video or e- con-
sultation. Face- to- face consultations were those carried 
out in GP practices as well as visits to patients’ homes or 
nursing homes. See online supplemental file 1 for further 
details.
Outcomes
Pre- existing code lists14 15 were used to identify records of 
potential cancer indicators associated with a consultation. 
The indicators were collated from the clinical features 
of undiagnosed cancer (symptoms, signs, abnormal test 
results or diagnoses) listed in the National Institute for 
Health and Care Excellence guidance on the recogni-
tion and referral of suspected cancer (NG12),16 using 
robust methods.15 Lists were developed using Read codes 
and subsequently mapped to SNOMED CT codes using 
medical dictionaries provided by the Clinical Practice 
Research Datalink for its AURUM dataset.17 There were 
a small number of Read codes in the predefined list 
which do not have equivalent SNOMED CT codes; the 
frequency with which these codes were used was so low as 
to be materially insignificant. New SNOMED codes added 
since the changeover from Read codes to SNOMED did 
not appear in our predefined lists so we checked this for 
common indicators cough and back pain, and found new 
codes were used very rarely.
SNOMED CT codes were used for this analysis. We 
excluded the indicator for new- onset diabetes (defined 
as a diabetes code in the absence of any diabetes moni-
toring in the previous 2 years), because we did not have 
the necessary patient records required to calculate this.
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A binary variable for ‘any potential cancer indicators’ 
was derived based on whether a consultation contained 
at least one potential cancer indicator code (yes) or did 
not (no). Using these consultation data, the number 
of patients reporting potential cancer indicators was 
calculated.
Each potential cancer indicator was categorised 
based on how many patients reported it in April–July 
2019: most commonly (≥0.5%), less commonly (0.1% 
to <0.5%), rarely (0.02% to <0.1%) and very rarely 
reported (<0.02%). We felt it was important to separate 
these, as the most commonly reported indicators include 
symptoms which often indicate acute illness or chronic 
illnesses other than cancer (eg, cough), whereas the less 
commonly/rarely reported indicators are more likely 
to be associated with cancer (eg, weight loss, lumps and 
masses).
Explanatory variables
Age (in July 2020) was split into four categories: 50–59 
years, 60–69 years, 70–79 years and 80+ years. Deprivation 
quintiles (measured by the index of multiple depriva-
tion (IMD) score) were calculated using the IMD deciles 
recorded in the patient record, which are based on lower 
super output areas of residence. Ethnicity was derived by 
mapping ethnicity descriptions in primary care records 
to one of five ethnicity categories: white, Asian, black, 
mixed and other (see online supplemental file 1). Pres-
ence of a mental health condition was defined as either 
severe mental illness (defined according to the Quality 
and Outcomes Framework (QOF) rules18), diagnosed 
depression or prescribed antidepressants (excluding 
tricyclics, commonly used for non- mental health- related 
conditions) in the 3 months prior to July 2020. These 
conditions are part of QOF and are therefore likely to 
be coded more reliably within GP medical records than 
other conditions. Sex and shielding status (as of July 
2020) were obtained directly from patients’ primary care 
records.
Statistical analysis
The number and percentage of patients reporting poten-
tial cancer indicators during our reporting periods are 
presented. In addition, consultation rates (and percent-
ages with potential cancer indicators) are reported per 
1000 registered patients. Practice list sizes were based 
on July 2020 data, and adjusted to account for historic 
list sizes using NHS digital data19 (‘adjusted list size’; see 
online supplemental file 1).
Changes in proportions of patients presenting (per 
practice) with any potential cancer indicator in April–July 
2020 compared with April–July 2019 were investigated 
using negative binomial regression models with counts 
of patients presenting with potential cancer indicators 
as the outcome; incidence rate ratios (IRRs) and 95% 
CIs are reported. Consultation year was fitted as a fixed 
effect, GP practice as a random effect and adjusted prac-
tice list size (per level of covariate where appropriate) as 
the offset. Fixed effects for each of the categorical patient 
characteristics of interest (age, sex, ethnicity, IMD quin-
tile, mental health status and shielding status), along with 
an interaction term between each of these covariates and 
consultation year, were separately fitted to the model; 
interaction p values are presented and changes in propor-
tions of patients with potential cancer indicators are only 
presented separately for each level of a covariate if the 
interaction p value was <0.05. Model validity was checked 
using standard methods; outliers which disrupted model 
fit were removed.
To investigate the effect of consultation provision (ie, 
face- to- face vs remote consulting), we looked at propor-
tions of consultations with potential cancer indicators 
(out of all consultations) rather than proportions of 
patients. Separate models were fitted for consultations 
with GPs and nurses/paramedics. Models were similar to 
those described above, with number of consultations as 
the outcome, a fixed effect for consultation provision and 
an interaction with year, GP practice as a random effect 
and total numbers of consultations per practice per level 
of consultation provision as the offset.
For individual potential cancer indicators, unadjusted 
IRRs for the percentage of patients consulting in April–
July 2020 compared with 2019 are presented to help 
interpretation; 95% CIs are included to indicate uncer-
tainty but, owing to the large number of indicators and 
resultant issues with multiple testing, no multivariate 
modelling was performed. Indicators with p<0.0008 have 
been highlighted. This p value threshold was calculated 
using the Bonferroni correction, which reduces the stan-
dard 0.05 by a factor of the number of tests performed to 
allow for multiple testing. Within the individual cancer 
indicators, we highlighted eight alarm symptoms: visible 
haematuria, rectal bleeding, haematemesis, haemop-
tysis, jaundice, breast lump, postmenopausal bleeding in 
women aged 55 years and over and dysphagia. These are 
symptoms that warrant investigation in their own right 
because of their predictive power for cancer.16
Stata V.15.1 was used to conduct all data checking, 
cleaning and analyses.
Patient and public involvement
A patient and public involvement group reviewed the 
RAPCI proposal before submission, agreed with the 
importance of the study and commented on the plain 
language summary. A meeting was also held to discuss 
preliminary findings of the main study,4 where a number 
of points were raised which supported the current work. 
These included participants highlighting that they felt 
things were missed during their telephone consultations 
because the GP could not see them.
RESULTS
The 21 GP practices recruited covered 25% of Bristol, 
North Somerset and South Gloucestershire CCG. Selec-
tion of practices aimed to be representative of the region 
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in terms of deprivation, size, location and ethnicity. The 
practices covered 350 966 registered patients (as of July 
2020). Of these 123 947 were over 50.
During April–July 2019, of the 123 947 registered 
patients over 50, 69 254 (56%) consulted, and 21 252 
(17%) of patients reported a potential cancer indicator. 
In April–July 2020, of 126 466 registered patients over 50, 
56 314 (45%) consulted and 13 829 (11%) reported an 
indicator. This comprised 1837 consultations per 1000 
patients registered (with indicators reported in 16% of 
consultations) in April–July 2019 and 1663 consultations 
per 1000 patients (with indicators reported in 13% of 
consultations) in April–July 2020. Figures 1 and 2 demon-
strate that patients consulting, and consultation rates, 
substantially dropped in April 2020 (following UK lock-
down), and while consultation rates had recovered by July 
2020, the proportion of patients who consulted had not.
Furthermore, the percentage of patients reporting 
potential cancer indicators (figure 1), and percentage 
of consultations with indicators reported (figure 2), 
also dropped in April 2020. Both had increased by July 
2020 (to 4.3% of patients and 13.5% of consultations), 
but neither had recovered to pre- COVID levels (6.0% 
of patients and 15.2% of consultations in July 2019). 
Patients who consulted in 2020 were of similar age, sex, 
IMD quintile and ethnicity as those consulting in 2019, 
but may have been more likely to have a mental health 
condition or be shielding (table 1).
There was a 36% reduction in patients who reported 
potential cancer indicators in April–July 2020 compared 
with 2019 (IRR 0.64, 95% CI 0.62 to 0.67, p<0.001; 
table 2). This reduction was stable across age group (inter-
action p value=0.136), sex (p=0.467), ethnicity (p=0.471), 
IMD quintile (p=0.585) and shielding status (p=0.099), 
but differed by mental health status (p<0.001; table 2). 
The reduction in reporting of these indicators was less 
pronounced in patients with a mental health condition 
(IRR 0.73, 95% CI 0.69 to 0.77, p<0.001) than patients 
without a mental health condition (IRR 0.63, 95% CI 0.61 
to 0.66, p<0.001; table 2).
The proportion of consultations where potential 
cancer indicators were reported differed by consultation 
provision for both GP and nurse/paramedic consul-
tations (both p<0.001; table 3). In GP consultations, 
proportions of face- to- face consultations with indicators 
reported dropped between 2019 and 2020 (IRR 0.84, 
95% CI 0.76 to 0.92, p≤0.001) and increased for remote 
consultations (IRR 1.17, 95% CI 1.07 to 1.29, p=0.001; 
table 3). For nurse/paramedic consultations, this finding 
was even more extreme (IRR 0.61, 95% CI 0.44 to 0.83, 
p=0.002 for face- to- face consultations; IRR 1.60, 95% CI 
1.10 to 2.33, p=0.014 for remote consultations). Despite 
this increase in the proportion of potential cancer indi-
cators in remote consultations, in both years GP remote 
consultations were less likely to report potential cancer 
indicators compared with GP face- to- face consultations 
(table 3).
The proportion of patients reporting all commonly 
reported indicators reduced between the two periods 
(unadjusted IRR=0.59), with the biggest reductions in 
chest infections (IRR=0.25), fever (IRR=0.36), coughs 
(IRR=0.44) and fatigue (IRR=0.50; table 4). For less 
commonly reported and rarely reported indicators, 
the reductions were less marked (IRR=0.75 and 0.76, 
respectively). Erectile dysfunction (IRR=0.40), irritable 
bowel syndrome (IRR=0.49), limp/gait abnormalities 
(IRR=0.39), night sweats (IRR=0.43) and lymphade-
nopathy (IRR=0.43) saw the largest reductions in these 
groups. Less common indicators which were similar or 
even increased were: nausea (IRR=1.00), weight loss 
(IRR=1.07) and constipation (IRR=1.18). All of the eight 
alarm symptoms reduced in frequency. Only haematuria 
(IRR=0.67) saw a significant reduction after correcting 
for multiple testing (ie, p<0.0008), but at an aggregated 
level there was a significant reduction in patients who 
reported at least one cancer alarm symptom (IRR 0.73, 
95% CI 0.68 to 0.79, p<0.0008; table 4).
Figure 1 Proportion of patients consulting and proportion 
consulting with potential cancer indicators.
Figure 2 Number of consultations per 1000 patients and 
proportion of those with potential cancer indicators.
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In April 2020, coinciding with UK lockdown, both the 
proportion of patients consulting, and those presenting 
with features potentially indicating cancer reduced 
compared with April 2019. By July 2020, although overall 
consultation rates had returned to previous levels, the 
proportion of patients consulting, and the proportion 
with potential cancer indicators remained lower than 
the previous year. The reduction in potential cancer 
indicator reporting did not differ by age, sex, ethnicity, 
deprivation or shielding status, but was less evident in 
patients with mental health conditions than those with no 
mental health conditions. Our results show that, despite 
an increase in consultations (for any reason) in patients 
aged 85+ years and patients advised to shield (shown in 
our previous paper4), these have not resulted in higher 
levels of potential cancer indicator reporting in these 
groups, perhaps indicating these consultations were for 
routine assessment rather than to address new issues. 
Table 1 Characteristics of registered and consulting patients in participating practices
All patients registered in 
July 2020
(n=126 466)*
Patients consulting in April–July 
2019
(n=69 254)
Patients consulting in 
April–July 2020
(n=56 314)
N % N % N %
Age (years)
  50–59 44 614 35.3 20 830 30.1 16 711 29.7
  60–69 33 338 26.4 17 765 25.7 14 252 25.3
  70–79 27 536 21.8 17 512 25.3 14 066 25.0
  80+ 20 978 16.6 13 147 19.0 11 285 20.0
Gender
  Male 61 798 48.9 30 949 44.7 25 129 44.6
  Female 64 668 51.1 38 305 55.3 31 185 55.4
Index of multiple deprivation quintile
  1 (most deprived) 19 392 15.4 10 877 15.8 9355 16.7
  2 15 907 12.7 8792 12.8 7403 13.2
  3 18 665 14.9 10 197 14.8 8151 14.5
  4 28 169 22.4 15 174 22.0 12 236 21.80
  5 (least deprived) 43 500 34.6 23 861 34.6 18 888 33.7
  Missing 833 353 281
Ethnicity†
  White 91 401 93.2 52 262 93.3 42 512 93.3
  Asian 2507 2.6 1443 2.6 1161 2.5
  Black 2963 3.0 1655 3.0 1374 3.0
  Mixed 1000 1.0 532 0.9 425 0.9
  Other 227 0.2 111 0.2 89 0.2
  Missing 28 368 13 251 10 753
MH status
  No MH conditions 111 143 87.9 57 923 83.6 45 885 81.5
  1+ MH condition 15 323 12.1 11 331 16.4 10 429 18.5
Shielding status
  Not advised to shield 116 518 92.1 61 417 88.7 48 305 85.8
  Advised to shield 9948 7.9 7837 11.3 8009 14.2
*The corresponding number of patients registered in 2019 was 123 947. As we only had patient characteristic data for the 21 participating 
practices for patients registered on 1 July 2020, we imputed the 2019 list sizes using NHS digital historical list sizes.
†White includes British, white British, mixed British and other white background. Black includes African, Caribbean, Somali and black British. 
Asian includes Indian, British Indian, Pakistani, Chinese and other Asian background. Mixed includes white and black Caribbean, white and 
Asian, white and African, other mixed white and other mixed background. Other includes Turkish, Arab, Iranian, other ethnic non- mixed and 
any other group. See online supplemental file 1 for further details.
MH, mental health; NHS, National Health Service.
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Patients with mental health conditions did, however, have 
a smaller reduction in presentations with features poten-
tially indicating cancer than other patients, perhaps as a 
result of this increased focus on them from GPs.4 Between 
2019 and 2020, there was a large reduction in face- to- face 
consultations which involved reporting of cancer indica-
tors, which was not fully compensated for by an increase 
in reporting of these indicators in remote consultations. 
Of the most commonly reported indicators, chest infec-
tions, fever, coughs and fatigue reduced most dramati-
cally. The reduction in ‘alarm’ indicators (27%) was less 
pronounced than the overall reduction (36%) but was 
still significant (p<0.0008).
Strengths and limitations
To our knowledge, this is the first paper to assess the effect 
of the COVID-19 pandemic on potential cancer indicator 
reporting in UK primary care. The analysis is based on a 
comprehensive list of potential cancer indicators, developed 
and validated by price, which has been used in previous 
research and is available on request.14 15 Our analysis included 
a large number of patients (>126 000) aged 50+ years from a 





Change in proportion of patients with 
potential cancer indicators
(2020 vs 2019)
N %* N %* IRR 95% CI P value
Overall 21 252 17 13 829 11 0.64 0.62 to 0.67 <0.001
Age (years) 0.136†
  50–59 6217 14 4083 9 0.65 0.61 to 0.69 <0.001
  60–69 5398 17 3368 10 0.61 0.58 to 0.65 <0.001
  70–79 5457 20 3449 13 0.62 0.59 to 0.67 <0.001
  80+ 4180 20 2929 14 0.68 0.64 to 0.73 <0.001
By sex 0.467†
  Male 9202 15 5905 10 0.63 0.60 to 0.67 <0.001
  Female 12 050 19 7924 12 0.65 0.62 to 0.68 <0.001
By ethnicity ‡ 0.471†
  White 15 910 18 10 340 11 0.64 0.61 to 0.68 <0.001
  Asian 590 24 357 14 0.58 0.50 to 0.69 <0.001
  Black 710 24 497 17 0.68 0.58 to 0.80 <0.001
  Mixed 193 20 106 11 0.55 0.42 to 0.70 <0.001
  Other 40 18 25 11 0.60 0.36 to 1.00 0.050
By index of multiple deprivation quintile 0.585†
  1 (most deprived) 3916 21 2662 14 0.67 0.63 to 0.72 <0.001
  2 2978 19 1981 12 0.64 0.60 to 0.69 <0.001
  3 3158 17 2052 11 0.63 0.59 to 0.68 <0.001
  4 4607 17 2999 11 0.63 0.59 to 0.67 <0.001
  5 (least deprived) 6469 15 4053 9 0.62 0.58 to 0.67 <0.001
By MH status <0.001†
  No MH conditions 17 338 16 10 924 10 0.62 0.60 to 0.64 <0.001
  1+ MH condition 3914 26 2905 19 0.73 0.69 to 0.77 <0.001
By shielding status 0.099†
  Not advised to shield 17 956 16 11 564 10 0.63 0.61 to 0.66 <0.001
  Advised to shield 3296 34 2265 23 0.68 0.63 to 0.72 <0.001
*Percentages are calculated out of all patients in each category.
†P values presented on the blue rows are the p values for the interaction between year and the given characteristic; IRR only presented by 
each level of a characteristic if this p<0.05.
‡White includes British, white British, mixed British and other white background. Black includes African, Caribbean, Somali and black British. 
Asian includes Indian, British Indian, Pakistani, Chinese and other Asian background. Mixed includes white and black Caribbean, white and 
Asian, white and African, other mixed white and other mixed background. Other includes Turkish, Arab, Iranian, other ethnic non- mixed and 
any other group. See online supplemental file 1 for further details.
IRR, incidence rate ratio; MH, mental health.
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diverse range of backgrounds, and as changes in service provi-
sion due to the pandemic have affected the whole country, 
our findings are likely to be generalisable to other areas of 
England. As all patients were included, there was no selec-
tion bias within practices. We endeavoured to select practices 
that were representative of the region but, as participation 
was voluntary, there may have been some selection bias at a 
practice level. However, this is unlikely to have changed the 
conclusions regarding reductions in potential cancer indica-
tors, as there is no reason to suppose research active prac-
tices would have a greater reduction than other practices. 
The representativeness of the data is best demonstrated with 
reference to the full RAPCI dataset (350 966 patients) not 
just the sample of 50+ patients in this dataset. The age and 
gender profile of the RAPCI data are representative of the 
UK. The proportion of ethnic minorities in the RAPCI data 
(12%) is representative of the CCG, but slightly less than the 
UK as a whole.20 The deprivation mix was slightly polarised; a 
fully representative sample would have approximately 20% in 
each quintile. The full RAPCI dataset had 20% in the bottom 
and fourth quintile but 27% in the most affluent so the 
second and third quintiles were slightly under- represented. 
Except for ethnicity, missing data about patient characteris-
tics were low. Twenty- six per cent of ethnicity data was missing 
in the RAPCI dataset (22% in the over 50s subset used for this 
paper). This may have led to information bias.
There are several limitations which pertain to the recording 
of potential cancer indicators. First, some symptoms and 
signs may have been reported in free text rather than using 
clinical codes,21 or may have been recorded in administra-
tion notes not associated with consultations. Furthermore, 
as described in the ‘Methods’ section, there were a small 
number of Read codes in the predefined list which do not 
have equivalent SNOMED CT codes, although the frequency 
with which these codes were used was so low as to be materi-
ally insignificant. These issues may have resulted in systematic 
under- reporting of potential cancer indicators; however, this 
is likely to be similar in both years and therefore should not 
affect the comparative findings. A further limitation was that 
new SNOMED codes added since the changeover from Read 
codes to SNOMED did not appear in our predefined lists, 
an issue which would affect April–July 2020 but not 2019; 
however, in checking the common indicators cough and 
back pain, we found new codes were used very rarely (data 
not shown). Finally, for indicators to be of concern as possible 
harbingers of cancer, they are sometimes qualified by age at 
onset, or as persistent or unexplained in National Institute 
for Health and Care Excellence suspected cancer guidance 
(NG12). Therefore, we limited our analysis to patients over 
50 years of age (because cancer is more common in older 
patients) but were unable to take account of whether symp-
toms were persistent or unexplained. This limitation applies 
to other studies based on routine records and using similar 
methods,14 but the effect may be to inflate our estimates of 
potential cancer indicators.
Comparison with other literature
Few other studies have looked at the content of primary 
care consultations following UK lockdown during the 
COVID-19 pandemic. Analysis of primary care data from 
a deprived urban population found that diagnoses of 
common conditions decreased substantially between 
March and May 2020, suggesting a large number of 
patients may have undiagnosed conditions resulting from 
changes in access post- lockdown.22 Our study adds to 
these findings for cancer- specific diagnoses.
Cancer screening programmes, estimated to account for 
about 5% of cancer diagnoses, were suspended in the wake of 
the pandemic.10 This made symptom- based diagnosis all the 
more urgent. UK lockdown could have affected symptom- 
based reporting via the move to remote consulting. Research 
has shown that telephone and video consultations result in 
Table 3 Consultations (per 1000 patients) with potential cancer indicators reported in April–July 2020 compared with 2019
April–July 2019 April–July 2020
Change in rates of consultations with 
potential cancer indicators
(2020 vs 2019)
GP consultations N %* N %* IRR 95% CI P value
Overall 236.5 19 176.4 15 0.79 0.74 to 0.84 <0.001
By consultation provision <0.001†
  Face- to- face 187.8 21 25.4 17 0.84 0.76 to 0.92 <0.001
Remote 48.7 13 151.0 14 1.17 1.07 to 1.29 0.001
Nurse/Paramedic consultations N % N % IRR 95% CI P value
Overall 53.6 9 31.9 7 0.69 0.56 to 0.85 <0.001
By consultation provision <0.001†
  Face- to- face 50.2 10 15.7 6 0.61 0.44 to 0.83 0.002
  Remote 3.4 7 16.1 9 1.60 1.10 to 2.33 0.014
IRRs and corresponding 95% CIs and p values from negative binomial models.
*Percentages are calculated out of all consultations in each category.
†P values presented on these rows are the p values for the interaction between year and consultation provision.
GP, general practitioner; IRR, incidence rate ratio.
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95% CI (bold 
indicates 
p<0.0008)N % N %
Any potential cancer indicator 21 252 17.15 13 829 10.93 0.64 0.62 to 0.65
Cancer alarm symptoms (see asterisk 
(*))
1801 1.45 1344 1.06 0.73 0.68 to 0.79
  
Most commonly reported indicators (≥0.5% of patients in 2019)
Any commonly reported indicator 16 632 13.42 10 054 7.95 0.59 0.58 to 0.61
Chest infection 1427 1.15 370 0.29 0.25 0.23 to 0.29
Fever 1216 0.98 443 0.35 0.36 0.32 to 0.40
Cough 3125 2.52 1397 1.10 0.44 0.41 to 0.47
Fatigue 1284 1.04 655 0.52 0.50 0.45 to 0.55
Urinary tract infection 760 0.61 394 0.31 0.51 0.45 to 0.57
Pain in shoulder 1307 1.05 785 0.62 0.59 0.54 to 0.64
Proteinuria 697 0.56 437 0.35 0.61 0.54 to 0.69
Non- visible haematuria 979 0.79 616 0.49 0.62 0.56 to 0.68
Pain in abdomen 1908 1.54 1301 1.03 0.67 0.62 to 0.72
Haematuria* 897 0.72 612 0.48 0.67 0.60 to 0.74
Shortness of breath 2382 1.92 1650 1.30 0.68 0.64 to 0.72
Pain in chest 1180 0.95 830 0.66 0.69 0.63 to 0.75
Back pain/Backache 2659 2.15 1887 1.49 0.70 0.66 to 0.74
Lower urinary tract symptoms 1402 1.13 1027 0.81 0.72 0.66 to 0.78
Compressed trachea 864 0.70 638 0.50 0.72 0.65 to 0.80
Diarrhoea 860 0.69 645 0.51 0.74 0.66 to 0.82
Less commonly reported indicators (0.1% to <0.5% of patients in 2019)
Any less commonly reported indicator 6585 5.31 5008 3.96 0.75 0.72 to 0.77
Erectile dysfunction 363 0.29 148 0.12 0.40 0.33 to 0.49
Irritable bowel syndrome 194 0.16 97 0.08 0.49 0.38 to 0.63
Gynae abnormalities (eg, menstrual 
disorders and unusual bleeding)
190 0.15 99 0.08 0.51 0.40 to 0.65
Pain in throat (eg, tonsilitis) 201 0.16 109 0.09 0.53 0.42 to 0.67
Iron deficiency anaemias 477 0.38 273 0.22 0.56 0.48 to 0.65
Change in bowel habit 281 0.23 161 0.13 0.56 0.46 to 0.68
Pain in breast 170 0.14 99 0.08 0.57 0.44 to 0.74
Bruising 208 0.17 126 0.10 0.59 0.47 to 0.74
Prostate- specific antigen raised/abnormal 173 0.14 121 0.10 0.69 0.54 to 0.87
Postmenopausal bleeding* 144 0.12 101 0.08 0.69 0.53 to 0.89
Pain in pelvis 388 0.31 280 0.22 0.71 0.60 to 0.83
Pruritus 356 0.29 259 0.20 0.71 0.61 to 0.84
Vomiting 245 0.20 180 0.14 0.72 0.59 to 0.88
Dyspepsia 590 0.48 450 0.36 0.75 0.66 to 0.85
Distension of abdomen 142 0.11 111 0.09 0.77 0.59 to 0.99
Reflux 560 0.45 439 0.35 0.77 0.68 to 0.87
Lump in breast* 208 0.17 170 0.13 0.80 0.65 to 0.99
Recurring infections 366 0.30 304 0.24 0.81 0.70 to 0.95
Rectal bleeding* 357 0.29 303 0.24 0.83 0.71 to 0.97
Continued
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fewer problems being identified than face- to- face consul-
tations.23 Lockdown could also have influenced patients to 
only contact primary care if they thought their problem was 
serious, which is likely to be reflected in the reduced propor-
tion of patients consulting found in our study.
Early in the pandemic, GPs predicted that patients with 
well- recognised red- flag symptoms, such as a new lump or 
rectal bleeding, would continue to present to primary care, 
but that vaguer cancer symptoms such as fatigue, change 
in bowel habit and weight loss might be dismissed by the 
patient as trivial and not presented to primary care.10 This 
was supported by our findings, which show that the most 
common symptoms reduced more substantially than less 






95% CI (bold 
indicates 
p<0.0008)N % N %
Dysuria 196 0.16 169 0.13 0.85 0.68 to 1.04
Vaginal discharge 153 0.12 134 0.11 0.86 0.68 to 1.09
Dysphagia* 171 0.14 151 0.12 0.87 0.69 to 1.08
Lump (excluding breast) 402 0.32 375 0.30 0.91 0.79 to 1.06
Nausea 147 0.12 150 0.12 1.00 0.79 to 1.26
Weight loss 218 0.18 239 0.19 1.07 0.89 to 1.30
Constipation 545 0.44 655 0.52 1.18 1.05 to 1.32
Rarely reported indicators (0.02% to <0.1% of patients in 2019)
Any rarely reported indicator 909 0.73 702 0.56 0.76 0.68 to 0.84
Limp/Gait abnormalities 25 0.02 10 0.01 0.39 0.17 to 0.85
Night sweats 75 0.06 33 0.03 0.43 0.28 to 0.66
Lymphadenopathy 86 0.07 38 0.03 0.43 0.29 to 0.64
Haemoptysis* 62 0.05 34 0.03 0.54 0.34 to 0.83
Abnormal chest X- ray 28 0.02 17 0.01 0.60 0.31 to 1.13
Hoarseness of voice 101 0.08 65 0.05 0.63 0.45 to 0.87
Pain in testis 71 0.06 46 0.04 0.63 0.43 to 0.93
Pain in bones 118 0.10 86 0.07 0.71 0.53 to 0.95
Possible bone and soft tissue sarcoma 
symptoms (eg, abnormal X- ray)
30 0.02 22 0.02 0.72 0.40 to 1.29
Chest/Breathing abnormalities 26 0.02 20 0.02 0.75 0.40 to 1.40
Mass in neck 115 0.09 89 0.07 0.76 0.57 to 1.01
Mass in testis 102 0.08 79 0.06 0.76 0.56 to 1.03
Superior vena cava syndrome 39 0.03 38 0.03 0.95 0.59 to 1.53
Testis swelling/Abnormalities 31 0.03 32 0.03 1.01 0.60 to 1.71
Appetite loss 49 0.04 76 0.06 1.52 1.05 to 2.22
Mass in abdomen 42 0.03 79 0.06 1.84 1.25 to 2.75
Very rarely reported indicators (<0.02% of patients in 2019)
Any very rarely reported indicator† 141 0.11 108 0.09 0.75 0.58 to 0.97
Bold face indicates a change over time based on 95% CI adjusted for multiple testing using the Bonferroni correction (P<0.0008).
*'Alarm’ symptoms, which warrant investigation in their own right in NICE suspected cancer guidelines, because of their predictive power for 
cancer: visible haematuria, rectal bleeding, haematemesis, haemoptysis, jaundice, breast lump, postmenopausal bleeding in women aged 55 
years and over and dysphagia.
†Very rare indicators affecting <0.02% of patients (25 individuals) in April–July 2019 clubbing of fingers, ulceration of vulva, prostate 
abnormalities on digital rectal exam, nipple retraction, skin lesion, mass in thyroid, jaundice, spinal cord compression, mass in pelvis, faecal 
occult blood test, abnormal skin on breast, nipple discharge, haematemesis and 12 additional indicators with incidence <5 patients in April–
July 2019.
‡Indicators are ordered from largest to smallest reduction (by IRR) within each commonality grouping. These figures only include indicators 
coded in routinely collected records using SNOMED codes. In some cases, GPs/nurses may enter symptoms in free text, and/or only code 
their diagnosis, which may lead to under- reporting here; this under- recording is likely to be similar in both years.
IRR, incidence rate ratio; NICE, National Institute for Health and Care Excellence.
Table 4 Continued
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symptoms (such as chest infections and sore throats) will be 
attributable to causes other than cancer, such as viral infec-
tions, and the figures should be interpreted in this context. 
Social distancing and lockdown has resulted in less infection 
overall as demonstrated by the Royal College of General Prac-
titioners research and surveillance centre data, which shows 
a marked reduction in weekly reported incidence of asthma, 
intestinal infectious diseases and upper and acute respiratory 
tract infections from week 12 of 2020.24 Nonetheless, the 
reductions are still concerning, especially for older patients. 
A 2020 survey from Cancer Research UK suggested GPs 
are particularly worried about older people not consulting 
with potential cancer symptoms compared with before the 
pandemic.5 Analysis of the national cancer registry in the 
Netherlands shows reduction in cancer diagnosis at the start 
of the pandemic was particularly pronounced in patients 
aged 80 years or over.9 The Netherlands operates a similar GP 
gatekeeper model to the UK,25 and the authors of this Dutch 
paper suggested that the move to remote GP consulting 
combined with patients delaying consultation about poten-
tial non- specific cancer symptoms may have contributed to 
the reduction in diagnoses.9 In the current study, we show 
that this suggestion is supported for the set of UK practices 
we analysed. Although we did not observe a greater reduc-
tion in symptom reporting in patients aged 80 years or over, 
potential symptoms in over 80s are more likely to result in 
a cancer diagnosis; therefore, the fact that reductions were 
similar across all age groups, rather than less of a reduction 
seen in older age groups, is of concern.
Implications for policy and practice
Combined with our previous work,4 the Cancer Research UK 
report,5 and reductions in cancer diagnoses,6 7 these findings 
suggest that patients are less likely to report potential cancer 
indicators than before the COVID-19 pandemic, particularly 
for more common symptoms such as fever and coughs and 
for alarm symptoms. In the context of repeated lockdowns, 
it is therefore extremely important that the general public 
are advised that they should still consult with primary care 
if they have persistent symptoms that might indicate cancer. 
Furthermore, GPs and nurses should be encouraged to ask 
more probing questions during remote consulting, as they 
may miss symptoms which may have previously been picked 
up from non- verbal cues and possibly a more open discussion 
face- to- face.
CONCLUSION
The proportion of patients consulting with primary care, 
as well as those reporting potential cancer indicators, 
reduced during the first wave of the COVID-19 pandemic. 
While there has been an increased rate of potential cancer 
indicators reported in remote consultations compared 
with last year, there are still lower rates in remote GP 
consultations than in face- to- face, suggesting remote 
consulting may be part of the reason for the reduction in 
reporting of potential cancer indicators.
Twitter Mairead Murphy @mairead_murf, Jeremy Horwood @JPHorwood and Chris 
Salisbury @prof_tweet
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